3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Glioma
2
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Melphalan
4
Irinotecan
4
Filgrastim
4
Cyclophosphamide
4
Busulfan
4
fludarabine
3
Topotecan
3
Temozolomide
3
Granulocyte Colony-Stimulating Factor
3
pegfilgrastim
2
liposomal doxorubicin
2
Thiotepa
2
Sirolimus
2
Peripheral Blood Stem Cell Transplantation
2
Doxorubicin
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
ribociclib
1
regorafenib
1
poly ICLC
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
olaparib
1
mocetinostat
1
lexatumumab
1
irinotecan sucrosofate
1
fludarabine phosphate
1
cixutumumab
1
ceritinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled